Hyaluronate–Peanut Agglutinin Conjugates for Target-Specific Bioimaging of Colon Cancer

Colon cancer is one of the most common death-related cancers in the world. For treating colon cancer, it is crucial to detect and remove malignant lesions early. Here, we developed hyaluronate (HA)–peanut agglutinin (PNA) conjugates for the bioimaging of colon cancer. The HA–PNA conjugates were successfully synthesized by the coupling reaction between aldehyde-modified HA and the N-terminal amine group of PNA. For diagnostic imaging, rhodamine B (RhoB) was chemically conjugated onto PNA in HA–PNA conjugates. After intraluminal injection of HA–PNA–RhoB conjugates into tumor-bearing mice, small-sized colon cancers could be effectively visualized by ex vivo imaging with an in vivo imaging system (IVIS) and a two-photon microscope. With these results taken together, we could confirm the feasibility of HA–PNA–RhoB conjugates as a bioimaging agent for detecting colon cancers

Le Peuple : organe quotidien du syndicalisme

07 novembre 19371937/11/07 (A17,N6134)-1937/11/07

Le Peuple : organe quotidien du syndicalisme

12 janvier 19381938/01/12 (A18,N6200)-1938/01/12

Additional file 9: Table S7. of The Rap activator Gef26 regulates synaptic growth and neuronal survival via inhibition of BMP signaling

Quantification of NMJ parameters for the experiments in Fig. 5b. (PDF 251 kb

Le Courrier

07 mars 18271827/03/07 (A0,N66)

Additional file 2: Figure S1. of The Rap activator Gef26 regulates synaptic growth and neuronal survival via inhibition of BMP signaling

Presynaptic requirement for Gef26 in synaptic growth regulation and characterization of satellite boutons. a Confocal images of anti-HRP-labeled NMJ 6/7 in C155-GAL4/+, C155-GAL4/+; UAS-gef26 RNAi /+, BG57-GAL4/+, and BG57-GAL4/UAS-gef26 RNAi third-instar larvae. Scale bar, 20 μm. b Quantification of total bouton number and satellite bouton number. c-e Confocal images of NMJ 6/7 stained with anti-HRP and anti-NC82 (c), anti-CSP (d), or anti-Dlg (e) for wild-type and gef26 6 /Df third-instar larvae. f Confocal images of NMJ 6/7 stained with anti-NC82 and anti-GluRIIC in wild-type and gef26 6 /Df third-instar larvae. The number of NMJs analyzed is indicated in each bar. Data are expressed as mean ± SEM. *P < 0.001. (TIFF 20874 kb

Presentation_1_An Herbal Drug, Gongjin-dan, Ameliorates Acute Fatigue Caused by Short-Term Sleep-Deprivation: A Randomized, Double-Blinded, Placebo-Controlled, Crossover Clinical Trial.PPTX

<p>Introduction:Gongjin-dan (GJD) is an herbal drug commonly used in Korea and China to combat fatigue, but there are only few clinical studies on its effectiveness and experimental studies on its mechanism of action, and no randomized controlled trial of GJD on the efficacy and mechanism of action has been reported. Here, we performed an exploratory study to evaluate both questions regarding GJD use in humans.</p><p>Methods: A randomized, double-blinded, placebo-controlled, crossover clinical trial was conducted in the Republic of Korea. Healthy male participants were recruited and randomly allocated to groups receiving GJD-placebo or placebo-GJD in sequence. Fatigue was artificially induced by sleep deprivation for 2 nights. The primary outcome was a change in serum cortisol level; levels of biomarkers for stress hormones as well as oxidative stress and immunologic factors were also assessed, and questionnaires on fatigue and sleep quality were conducted.</p><p>Results: Twelve and 11 participants were assigned to the GJD-placebo and placebo-GJD groups, respectively. Of all 23 participants, depending on crossover design, we analyzed a total of 20 participants for GJD, and 21 for placebo. An increase in serum cortisol appeared to be attenuated by GJD administration (p = 0.25), but the effect was not statistically significant; a similar pattern was observed in salivary cortisol levels (p = 0.14). Overall, GJD showed a tendency to reduce fatigue according to the Brief Fatigue Inventory (BFI, p = 0.07) and the Fatigue Severity Scale (FSS, p = 0.13) questionnaires. BFI and FSS scores in the first stage (before the crossover), however, were significantly improved (BFI, p = 0.02; FSS, p = 0.05) after GJD treatment (relative to placebo). GJD also seemed to improve sleep quality as assessed by the Leeds Sleep Evaluation Questionnaire (p = 0.06), with a significant improvement specifically in the condition “Getting To Sleep” (p = 0.02). Five participants experienced minor adverse events, but no adverse events were specific to the GJD administration period.</p><p>Conclusions: This trial produced the first clinical evidence that GJD might have anti-fatigue properties, especially under sleep deprivation; however, the investigation of cortisol-mediated mechanisms requires further larger-scale studies in the future.</p><p>Trial registration: World Health Organization International Clinical Trials Registry Platform KCT0001681 (http://apps.who.int/trialsearch/Trial2.aspx?TrialID=KCT0001681).</p

Adjusted odds ratios for dyslipidemic parameters according to each increase in log-transformed serum ferritin levels.

<p>Adjusted odds ratios for dyslipidemic parameters according to each increase in log-transformed serum ferritin levels.</p

Adjusted odds ratios for dyslipidemic parameters according to each increase in log-transformed serum ferritin levels.

<p>Adjusted odds ratios for dyslipidemic parameters according to each increase in log-transformed serum ferritin levels.</p

Principal clinical characteristics of Korean adolescents in the 2009–2010 Korean National Health and Nutrition Examination Survey.

<p>Principal clinical characteristics of Korean adolescents in the 2009–2010 Korean National Health and Nutrition Examination Survey.</p